Baxter International | BAX - Current Assets


Baxter International reported $6.99B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Abbott USD 25.51B 488M Mar/2026
AngioDynamics USD 161.35M 4.69M Sep/2025
Artivion USD 371.38M 13.86M Jun/2026
AtriCure USD 345.53M 31.84M Jun/2026
Baxter International USD 6.99B 142M Jun/2026
Becton, Dickinson and Co. USD 8.14B 127M Jun/2026
Boston Scientific USD 7.97B 712M Jun/2026
Cooper Companies USD 2.3B 166M Mar/2026
Dexcom USD 4.09B 245.1M Jun/2026
Edwards Lifesciences USD 6.82B 590.2M Jun/2026
Fresenius EUR 11.61B 456M Jun/2026
Globus Medical USD 2.22B 17.39M Jun/2026
Halozyme Therapeutics USD 933.02M 70.01M Jun/2026
ICU Medical USD 1.21B 2.34M Jun/2026
Inogen USD 203.72M 594K Sep/2025
Insulet USD 1.85B 139.6M Jun/2026
Integra LifeSciences USD 1.19B 19.46M Jun/2026
Intuitive Surgical USD 12.33B 807.5M Jun/2026
J&J USD 59.77B 601M Jun/2026
Laboratory Of America USD 3.81B 743.9M Jun/2026
Medtronic USD 24.79B 716M Mar/2026
Merit Medical Systems USD 1.11B 10.46M Jun/2026
Quest Diagnostics USD 2.84B 278M Jun/2026
Smith & Nephew USD 4.39B 240M Jun/2026
Stryker USD 14.42B 1.08B Jun/2026
Tandem Diabetes Care USD 804.64M 82.46M Jun/2026
Teleflex USD 1.88B 16.21M Jun/2026
Terumo JPY 906.6B 45.57B Jun/2026
Zimmer Biomet Holdings USD 5.1B 134.2M Jun/2026